Insulin resistance in patients with rheumatoid arthritis: effect of anti‐TNFα therapy

References

• Gabriel S. E., Crowson C. S., O'Fallon W. M. Comorbidity in arthritis. J Rheumatol 1999; 26: 2475–9
   PubMed Web of Science ®Google Scholar
• Mikuls T. R., Saag K. G. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 283–303
   PubMed Web of Science ®Google Scholar
• Maradit‐Kremers H., Nicola P. J., Crowson C. S., Ballman K. V., Gabriel S. E. Cardiovascular death in rheumatoid arthritis: a population‐based study. Arthritis Rheum 2005; 52: 722–32
   PubMed Web of Science ®Google Scholar
• Oliver J. E., Silman A. J. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006; 35: 169–74
   PubMed Web of Science ®Google Scholar
• Maseri A. Inflammation, atherosclerosis, and ischemic events – exploring the hidden side of the moon. N Engl J Med 1997; 336: 1014–16
   PubMed Web of Science ®Google Scholar
• Pasceri V., Yeh E. T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124–6
   PubMed Web of Science ®Google Scholar
• Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4–7
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868–74
   PubMed Web of Science ®Google Scholar
• Petersen A. M., Pedersen B. K. The anti‐inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154–62
   PubMed Web of Science ®Google Scholar
• Plomgaard P., Bouzakri K., Krogh‐Madsen R., Zierath J. R., Pedersen B. K. TNF‐alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of AS160 phosphorylation. Diabetes 2005; 54: 2939–45
   PubMed Web of Science ®Google Scholar
• Saghizadeh M., Ong J. M., Garvey W. T., Henry R. R., Kern P. A. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 1996; 97: 1111–16
   PubMed Web of Science ®Google Scholar
• Hotamisligil G. S., Arner P., Caro J. F., Atkinson R. L., Spiegelman B. M. Increased adipose tissue expression of tumor necrosis factor‐alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–15
   PubMed Web of Science ®Google Scholar
• Feingold K. R., Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992; 41((Suppl 2))97–101
   PubMed Web of Science ®Google Scholar
• Mishima Y., Kuyama A., Tada A., Takahashi K., Ishioka T., Kibata M. Relationship between serum tumor necrosis factor‐alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 119–23
   PubMed Web of Science ®Google Scholar
• Winkler G., Salamon F., Harmos G., Salamon D., Speer G., Szekeres O., et al. Elevated serum tumor necrosis factor‐alpha concentrations and bioactivity in type 2 diabetics and patients with android type obesity. Diabetes Res Clin Pract 1998; 42: 169–74
   PubMed Web of Science ®Google Scholar
• Uysal K. T., Wiesbrock S. M., Marino M. W., Hotamisligil G. S. Protection from obesity‐induced insulin resistance in mice lacking TNF‐alpha function. Nature 1997; 389: 610–14
   PubMed Web of Science ®Google Scholar
• Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti‐TNF‐alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881–5
   PubMed Web of Science ®Google Scholar
• Paquot N., Castillo M. J., Lefebvre P. J., Scheen A. J. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin‐resistant patients. J Clin Endocrinol Metab 2000; 85: 1316–19
   PubMed Web of Science ®Google Scholar
• Kiortsis D. N., Mavridis A. K., Vasakos S., Nikas S. N., Drosos A. A. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765–6
   PubMed Web of Science ®Google Scholar
• Paolisso G., Valentini G., Giugliano D., Marrazzo G., Tirri R., Gallo M., et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991; 40: 902–7
   PubMed Web of Science ®Google Scholar
• Svenson K. L., Pollare T., Lithell H., Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988; 37: 125–30
   PubMed Web of Science ®Google Scholar
• Wallace T. M., Levy J. C., Matthews D. R. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95
   PubMed Web of Science ®Google Scholar
• Roberts C. K., Barnard R. J. Effects of exercise and diet on chronic disease. J Appl Physiol 2005; 98: 3–30
   PubMed Web of Science ®Google Scholar
• Goldblatt F., Isenberg D. A. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005; 140: 195–204
   PubMed Web of Science ®Google Scholar
• Senn J. J., Klover P. J., Nowak I. A., Mooney R. A. Interleukin‐6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391–9
   PubMed Web of Science ®Google Scholar
• Senn J. J., Klover P. J., Nowak I. A., Zimmers T. A., Koniaris L. G., Furlanetto R. W., et al. Suppressor of cytokine signaling‐3 (SOCS‐3), a potential mediator of interleukin‐6‐dependent insulin resistance in hepatocytes. J Biol Chem 2003; 278: 13740–6
   PubMed Web of Science ®Google Scholar
• Klover P. J., Zimmers T. A., Koniaris L. G., Mooney R. A. Chronic exposure to interleukin‐6 causes hepatic insulin resistance in mice. Diabetes 2003; 52: 2784–9
   PubMed Web of Science ®Google Scholar
• Klover P. J., Clementi A. H., Mooney R. A. Interleukin‐6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417–27
   PubMed Web of Science ®Google Scholar
• Cai D., Yuan M., Frantz D. F., Melendez P. A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK‐beta and NF‐kappaB. Nat Med 2005; 11: 183–90
   PubMed Web of Science ®Google Scholar
• Kim H. J., Higashimori T., Park S. Y., Choi H., Dong J., Kim Y. J., et al. Differential effects of interleukin‐6 and ‐10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004; 53: 1060–7
   PubMed Web of Science ®Google Scholar
• Stouthard J. M., Oude Elferink R. P., Sauerwein H. P. Interleukin‐6 enhances glucose transport in 3T3‐L1 adipocytes. Biochem Biophys Res Commun 1996; 220: 241–5
   PubMed Web of Science ®Google Scholar
• Weigert C., Brodbeck K., Staiger H., Kausch C., Machicao F., Haring H. U., et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin‐6 in human myotubes through proteasome‐dependent activation of nuclear factor kappa B. J Biol Chem 2004; 279: 23942–52
   PubMed Web of Science ®Google Scholar
• Weigert C., Hennige A. M., Brodbeck K., Haring H. U., Schleicher E. D. Interleukin‐6 (IL‐6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser‐473 of Akt. Am J Physiol Endocrinol Metab 2005; 289: E251–7
   PubMed Web of Science ®Google Scholar
• Rotter V., Nagaev I., Smith U. Interleukin‐6 (IL‐6) induces insulin resistance in 3T3‐L1 adipocytes and is, like IL‐8 and tumor necrosis factor‐alpha, overexpressed in human fat cells from insulin‐resistant subjects. J Biol Chem 2003; 278: 45777–84
   PubMed Web of Science ®Google Scholar
• Lagathu C., Bastard J. P., Auclair M., Maachi M., Capeau J., Caron M. Chronic interleukin‐6 (IL‐6) treatment increased IL‐6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372–9
   PubMed Web of Science ®Google Scholar
• Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S. L., et al. Interleukin‐6‐deficient mice develop mature‐onset obesity. Nat Med 2002; 8: 75–9
   PubMed Web of Science ®Google Scholar
• Bastard J. P., Maachi M., Van Nhieu J. T., Jardel C., Bruckert E., Grimaldi A., et al. Adipose tissue IL‐6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2084–9
   PubMed Web of Science ®Google Scholar
• Pickup J. C., Mattock M. B., Chusney G. D., Burt D. NIDDM as a disease of the innate immune system: association of acute‐phase reactants and interleukin‐6 with metabolic syndrome X. Diabetologia 1997; 40: 1286–92
   PubMed Web of Science ®Google Scholar
• Carey A. L., Bruce C. R., Sacchetti M., Anderson M. J., Olson D., Saltin B., et al. Interleukin‐6 and tumor necrosis factor‐alpha are not increased in patients with type 2 diabetes: evidence that plasma IL‐6 is related to fat mass and not insulin responsiveness. Diabetologia 2004; 47: 1029–37
   PubMed Web of Science ®Google Scholar
• Petersen K. F., Dufour S., Befroy D., Garcia R., Shulman G. I. Impaired mitochondrial activity in the insulin‐resistant offspring of patients with type 2 diabetes. N Engl J Med 2004; 350: 664–71
   PubMed Web of Science ®Google Scholar
• Steensberg A., Fischer C. P., Sacchetti M., Keller C., Osada T., Schjerling P., et al. Acute interleukin‐6 administration does not impair muscle glucose uptake or whole body glucose disposal in healthy humans. J Physiol 2003; 548((Pt 2))631–8
   PubMed Web of Science ®Google Scholar
• Febbraio M. A., Hiscock N., Sacchetti M., Fischer C. P., Pedersen B. K. Interleukin‐6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 2004; 53: 1643–8
   PubMed Web of Science ®Google Scholar
• Petersen E. W., Carey A. L., Sacchetti M., Steinberg G. R., Macaulay S. L., Febbraio M. A., et al. Acute IL‐6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro: evidence that IL‐6 acts independently of lipolytic hormones. Am J Physiol 2004; 288: E155–62
   Google Scholar
• Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Treatment of rheumatoid arthritis with humanized anti‐interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial. Arthritis Rheum 2004; 50: 1761–9
   PubMed Web of Science ®Google Scholar
• Atlizumab: anti‐IL‐6 receptor antibody‐Chugai, anti‐interleukin‐6 receptor antibody‐Chugai, MRA‐Chugai. BioDrugs 2003; 17: 369–72
   PubMed Web of Science ®Google Scholar
• Choy E. H., Isenberg D. A., Garrood T., Farrow S., Ioannou Y., Bird H., et al. Therapeutic benefit of blocking interleukin‐6 activity with an anti‐interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial. Arthritis Rheum 2002; 46: 3143–50
   PubMed Web of Science ®Google Scholar
• Dahlqvist S. R., Engstrand S., Berglin E., Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy. Scand J Rheumatol 2006; 35: 107–11
   PubMed Web of Science ®Google Scholar